Merck launches full-cycle production of Glucophage in Russia

21 January 2019

Germany’s Merck KGaA (MRK: DE) has launched full-cycle production of its Glucophage (metformin), Glucophage Long drugs, designed for the treatment of potential diabetes and type 2 diabetes mellitus in Russia at the facilities of its Russian partner Nanolek in the Kirov region, according to recent statements of both companies.

The volume of production is estimated at 400 million tablets per year, which will be enough to meet the annual Russia’s needs for this drug, reports The Pharma Letter’s local correspondent.

According to Merck, in terms of output, the newly-launched Russian production will become one of the largest in the world for the company after its similar manufacturing units in France and Greece.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK